Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN versus CEFOTETAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN versus CEFOTETAN.
Cefazolin vs CEFOTETAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 6-8 hours; maximum 12 g/day.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
None Documented
None Documented
Clinical Note
moderateCefazolin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefotetan + Ethanol
1.8 hours in normal renal function; extends to 30–70 hours in end-stage renal disease (CrCl <10 mL/min).
3-4.5 hours (6-8 hours in renal impairment).
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary: <1%; fecal: negligible.
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."